Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow

Bone Marrow Transplantation

Volumn 22, Issue 2, 1998, Pages 131-136

  Hagglund, H ^a   Ringden O ^a   Remberger, M ^a   Lonnqvist B ^a   Sparrelid, E ^a   Tammik, L ^a   Kumlien, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic peripheral blood progenitor cell transplantation; Bone marrow transplantation; Engraftment; Graft versus host disease; Survival

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; N4 (BETA N ACETYLGLUCOSAMINYL)ASPARAGINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ASPARTYLGLYCOSAMINURIA; BACTEREMIA; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOMA; MALE; MONONUCLEAR CELL; MYELOMA; NEUTROPHIL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIBLING; SURVIVAL; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

EID: 0031927232     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701298     Document Type: Article

References (32)

1. Körbling M, Dorken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-532.
2. Kessinser A, Armitase JO, Landmark JD, Weisenbureer DD. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14: 192-196.
3. Kessinger A, Smith DM, Strandjord SE el al. Allogeneic transplantation of blood-derived. T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989: 4: 643-646.
4. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
5. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
6. Bensinger WI, Weaver CH, Appelbaum FR et al Transplanstation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
7. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
8. Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
9. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of shortterm engraftment and acute GVHD incidence in 33 cases. Bone Marrow Transplant 1996; 18: 35-40.
10. Ringden O, Potter MN, Oakhill A et al. Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplant 1996; 17 (Suppl. 2): 62-64.
11. Ringden O, Lönnqvist B, H́'gglund H et al. Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. Bone Marrow Transplant 1995; 16: 856-857.
12. Ringden O, Baryd I, Johansson B et al. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. Acta Radiol Oncol 1983; 22: 423-428.
13. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia; a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
14. Storb R, Dees HJ, Whitehead J et al. Methotrexate and cyclos - porine compared with cyclosporine alone for prophylaxis of acute graft-versus-host-disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
15. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
16. Ringden O, Bäckman L, Lönnqvist B et al. A randomized trial comparing use of cyclosporin and methotrexate for graftversus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41-51.
17. Olerup O, Zetterquist H, HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours; an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation, Tiss Antigen 1992; 39: 225-235.
18. Rinsden O, Nilsson B, Death bv sraft-versus-host disease associated with HLA-mismatch, high recipient age. low marrow cell dose, and splenectomy. Transplant 1985; 40: 39-44.
19. Glucksberg H, Storb R, Refer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplant 1974; 18: 295-304.
20. Sparrelid E, Hägglund H, Remberger M et al. Risk factors for septicemia during the aplastic period after allogeneic bone marrow transplantation. Transplant Proc 1995; 27: 3530.
21. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graftversus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
22. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 1977; 35: 1-39.
23. + ThyIdim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
24. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
25. Urbano-Ispizua A. Carreras E. Sierra J et al. Whether methotrexate administration in graft-versus-host disease prophylaxis significantly delays the engraftment in allogeneic peripheral blood progenitor cell transplantation. Blood 1995: 86: 836-837.
26. Ringdén O, Remberger M, Mattsson J et al Transplantation with unrelated bone marrow in leukemic patients above 40 years of age. Transplant Proc 1997; 29: 3145-3146.
27. Schmitz N, Bacigalupo A. Hasenclever D. Gratwohl A. Allogeneic bone marrow transplantation r.v rilgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukemia. Bone Marrow Transplant 1998: 21: 995-1003.
28. Ringden O, Bone marrow transplantation using unrelated donors for haematological malignancies. Med Oncol 1997; 14: 11-22.
29. Ringden O, Paulin T. Lönnqvist B et al. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Heinatol 1985; 13: 1062-1067.
30. Storb R, Prentice RL. Sullivan KM et al Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
31. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-1709.
32. Link H, Arseniev L, Ljungman P et al. Cytomegalovirus infections after allogeneic peripheral blood progenitor cell transplantation (PBPCT) - a survey of the Infectious Diseases Working Party of EBMT. Blood 1997; 90 (Suppl. 1): 544a.